10-QFiled 5 Nov 2026Industrials
Cognex CorpCGNX
Quarterly report (10-Q), period ending 4 Oct 2026
Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
The nightly ledger
Every 8-K, 10-Q and 10-K that AIR's companies filed on SEC EDGAR, and what each one changed in AIR's read. Material filings first, newest first — never ordered by price. For 8-K filing alerts, follow a company and turn on filing emails.
By event type: Acquisitions · Major contracts
Seven-day window, 2 weeks back · Material filings: 1629 · All filings: 1839
Thursday 5 Nov642 filings read · 590 material
10-QFiled 5 Nov 2026Industrials
Cognex CorpCGNX
Quarterly report (10-Q), period ending 4 Oct 2026
Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 5 Nov 2026Industrials
8-K · Item 2.02 — Results of operations
Q3 2026 revenue of $560.4M (+4.3% YoY) with gross margin expansion to 42% from 37%. GAAP net income of $26.8M vs. prior-year loss; adjusted EPS $2.44 vs. $2.03. Company reaffirms full-year guidance, expecting results at high end of range.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 5 Nov 2026All industries
Concentra Group Holdings Parent, Inc.CON
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
8-KFiled 5 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Q3 2026: Production up 21% QoQ to 20,145 NRI BOPD; sales volumes 5% higher at 1,698 MBOE; Adjusted EBITDAX increased 30% to $71.1M. Gabon Phase Three drilling complete; Baobab field (Côte d'Ivoire) resumed production with first lifting in August; Egypt drilling campaign ongoing. Q4 guidance projects 18% sales volume increase.
No notable change in AIR's read.
8-KFiled 5 Nov 2026All industries
NorthWestern Energy Group, Inc.NWE
8-K · Item 2.02 — Results of operations
Q3 2026 diluted GAAP EPS of $0.50 vs. $0.62 prior year, driven by Colstrip ownership costs and depreciation. Company affirms 2026 guidance ($3.68–$3.83 EPS) and long-term 4–6% growth. Merger with Black Hills pending Montana PSC approval expected by November 12, 2026.
No notable change in AIR's read.
8-KFiled 5 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Q3 2026 revenue increased 8.9% to $78.4M, but net income fell 9.7% to $12.6M YoY. Hampden House ramp-up cost $3.7M in net income impact. Same-property NOI grew 5.0%, FFO per share flat at $0.72.
No notable change in AIR's read.
8-KFiled 5 Nov 2026All industries
Gibraltar Industries, Inc.ROCK
8-K · Item 2.02 — Results of operations
Q3 2026 earnings beat on revenue (+54% via OmniMax acquisition) but adjusted EPS declined 11.4% YoY. Residential organic growth of 3.1% offset by weak end market (-13%). Agtech delayed by permit issues. Full-year 2026 guidance reduced significantly across all metrics.
Market attention has faded.
The shares became cheaper on AIR's value read.
The gap narrowed as the filings read less positively.
8-KFiled 5 Nov 2026All industries
Scansource, Inc.SCSC
8-K · Item 2.02 — Results of operations
Q1 FY27 net sales grew 30.1% YoY to $962.3M, but operating income fell 52.2% to $12.4M and diluted EPS declined 52.8% to $0.42. Gross margin compressed 238bp to 12.2% due to hardware mix and large deals. Bad debt expense of $4.5M impacted results.
The reported numbers improved.
Market attention has faded.
The gap closed as the filings read less positively.
The price trend weakened.
8-KFiled 5 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Q3 2026: Retail segment achieved record revenue ($1.5B) with 33.7% EBITDAR margins; Interactive segment loss narrowed to $18.3M from $76.6M YoY. Consolidated Adjusted EBITDA grew 46% to $284M. Balance sheet deleveraging continued.
The shares became dearer on AIR's value read.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 5 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Q3 2026 revenue declined 8% YoY to $54.4M; GAAP net loss of $5.6M; Adjusted EBITDA fell 51% YoY to $3.9M. IP Operations revenue collapsed 97% YoY. Offset partially by Benchmark Energy strength and improved per-share cash position.
The gap closed as the filings read less positively.
8-KFiled 5 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Q3 2026: $134.1M non-cash impairment of ANZ goodwill/intangibles due to international student immigration constraints. Net loss $98.3M vs. $26.6M profit YoY. ETS revenue +12% YoY; USHE enrollment -1.1% YoY; ANZ enrollment -9.1% YoY.
Market attention has faded.
The shares became dearer on AIR's value read.
The gap closed as the filings read less positively.
The price trend weakened.
10-QFiled 5 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
The shares became dearer on AIR's value read.
The gap closed as the filings read less positively.
The price trend weakened.
10-QFiled 5 Nov 2026Biotech
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 5 Nov 2026All industries
Coty Inc.COTY
Quarterly report (10-Q), period ending 30 Sep 2026
More of the market is starting to notice.
The shares became dearer on AIR's value read.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 5 Nov 2026Biotech
Collegium Pharmaceutical, IncCOLL
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 5 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
More of the market is starting to notice.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 5 Nov 2026All industries
Sonida Senior Living, Inc.SNDA
8-K · Item 2.02 — Results of operations
Q3 2026 results show 26.2% Adjusted EBITDA growth, 15.6% same-store NOI increase, occupancy gains of 200 bps to 88.6%, and RevPOR growth of 4.6%. Company completed $150.2M in acquisitions and refinanced debt favorably.
Progress is running ahead of attention.
10-QFiled 5 Nov 2026Biotech
Lexicon Pharmaceuticals, Inc.LXRX
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
10-QFiled 5 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
10-QFiled 5 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
8-KFiled 5 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Q3 2026 net sales increased 24% to $389.9M; net income swung to $304.5M profit vs. prior-year $90.7M loss. Adjusted EBITDA grew 20% to $223.5M. Company completed Monaco acquisition and rebranded to Perimeter Group Inc.
More of the market is starting to notice.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 5 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
More of the market is starting to notice.
The price trend strengthened.
8-KFiled 5 Nov 2026All industries
Pangaea Logistics Solutions Ltd.PANL
8-K · Item 2.02 — Results of operations
The shares became cheaper on AIR's value read.
The price trend strengthened.
10-QFiled 5 Nov 2026All industries
Pangaea Logistics Solutions Ltd.PANL
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became cheaper on AIR's value read.
The price trend strengthened.
8-KFiled 5 Nov 2026All industries
Eplus IncPLUS
8-K · Items 2.02, 5.02, 8.01 — Results of operations
ePlus reported Q2 FY2027 results with record gross billings exceeding $1B, net sales up 9.7%, gross profit up 11.2%, and adjusted EBITDA up 14.3%. Company raised full-year FY2027 guidance to upper single digits for net sales/gross profit and low double digits for adjusted EBITDA.
No notable change in AIR's read.
8-KFiled 5 Nov 2026Industrials
8-K · Item 2.02 — Results of operations
Q3 2026 revenue of $203.0M (+41% YoY) exceeded expectations; company raised full-year 2026 guidance to $764–$774M. Net income $17.1M ($0.46/share). Key catalysts include FDA approvals for ENHANCE Heart Part B and DENOVO Lung trials, first European transplant logistics tender win, and OCS Kidney on track for 2H 2027.
More of the market is starting to notice.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 5 Nov 2026Industrials
Bruker CorpBRKR
Quarterly report (10-Q), period ending 30 Sep 2026
More of the market is starting to notice.
The shares became dearer on AIR's value read.
The price trend strengthened.
8-KFiled 5 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Corsair beat Q3 guidance with $367M revenue (+6% YoY), $17M above high end. Adjusted EBITDA surged 38% to $22.4M. Full-year revenue and EBITDA guidance raised; Q4 outlook strong with double-digit peripheral growth expected.
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
8-KFiled 5 Nov 2026Biotech
8-K · Item 2.02 — Results of operations
Q3 2026 revenue of $37.7M exceeded prior year ($32.5M). neffy market share grew to 5% overall, 9% in targeted accounts. Company reduced SG&A 42% QoQ, reaffirmed path to cash flow breakeven by end-2027. Leadership strengthened; ARS-2 Phase 2b on track for Q1 2027 interim data.
Progress is running ahead of attention.
8-KFiled 5 Nov 2026All industries
Celcuity Inc.CELC
8-K · Item 2.02 — Results of operations
REVTORPYK (gedatolisib) launched commercially on September 30, 2026, for HR+/HER2- breast cancer. 91% of U.S. commercial/Medicare lives have coverage; 78% of top 36 strategic accounts have ordered. Positive Phase 3 VIKTORIA-1 data for PIK3CA mutant cohort submitted as sNDA.
No notable change in AIR's read.
8-KFiled 5 Nov 2026All industries
Viasat IncVSAT
8-K · Item 2.02 — Results of operations
Viasat reported Q2 FY2027 results with 3% YoY revenue growth to $1.2B, driven by 20% DAT segment growth. ViaSat-3 Flights 2 and 3 entered service as expected. Free cash flow improved 14% YoY to $78M; net leverage declined 0.3x to 3.2x.
Market attention has faded.
Progress is running ahead of attention.
10-QFiled 5 Nov 2026Biotech
Mannkind CorpMNKD
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
10-QFiled 5 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
8-KFiled 5 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Q3 2026: Net investment income $0.54/share (18% YoY adjusted growth), total investment income $45.9M (+23% YoY). Board declared $0.54/share total dividends (base $0.43 + supplemental $0.11) for Q4. Portfolio $1.4B across 99 companies; NAV $19.47/share.
Progress is running ahead of attention.
8-KFiled 5 Nov 2026Software / SaaS
JFrog LtdFROG
8-K · Item 2.02 — Results of operations
JFrog reported Q3 2026 revenue of $179.2M (+31% YoY), cloud revenue $101.5M (+60% YoY), and raised FY2026 guidance. Net dollar retention 124%, customers with $1M+ ARR grew 58% YoY to 112. Strong cash generation and platform adoption.
More of the market is starting to notice.
The shares became dearer on AIR's value read.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 5 Nov 2026Biotech
Enliven Therapeutics, Inc.ELVN
8-K · Item 2.02 — Results of operations
Enliven achieved FDA alignment on ENABLE-2 Phase 3 trial design for relcobatinib in CML, on track to initiate before year-end 2026. Strong cash position of $884M supports runway into 2030. R&D expenses increased YoY.
More of the market is starting to notice.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 5 Nov 2026Biotech
8-K · Item 2.02 — Results of operations
LB Pharmaceuticals reported Q3 2026 results with $403.8M cash runway extending beyond Q2 2029. Lead asset LB-102 Phase 3 NOVA-2 trial in schizophrenia on track for 1H 2027 topline data. Completed $150M private placement and appointed experienced CMO and CFO.
No notable change in AIR's read.
10-QFiled 5 Nov 2026Biotech
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
10-QFiled 5 Nov 2026Biotech
Quarterly report (10-Q), period ending 30 Sep 2026
The gap narrowed — attention is catching up.
The price trend strengthened.
10-QFiled 5 Nov 2026Banks
Trustmark CorpTRMK
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
10-QFiled 5 Nov 2026Biotech
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
8-KFiled 5 Nov 2026All industries
Cbl & Associates Properties IncCBL
8-K · Item 2.02 — Results of operations
CBL reported Q3 2026 results with same-center NOI up 3.8%, FFO adjusted per share up 23% YoY, portfolio occupancy up 130 bps to 91.5%, and comparable lease spreads of 6.8%. Company raised full-year guidance twice.
Market attention has faded.
The price trend weakened.
10-QFiled 5 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 5 Nov 2026All industries
Brighthouse Financial, Inc.BHF
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
8-KFiled 5 Nov 2026Biotech
Xeris Biopharma Holdings, Inc.XERS
8-K · Item 2.02 — Results of operations
Q3 2026 revenue grew 44% YoY to $107M, led by Recorlev (+93% to $71M). Company raised FY2026 guidance to $395–$405M and 2030 outlook to >$1B. Net income $11.3M vs $0.6M prior year; Adjusted EBITDA $30.8M.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 5 Nov 2026Software / SaaS
Five9, Inc.FIVN
8-K · Item 1.01 — Material agreement
Five9 announced acquisition of Level AI for $325M cash. Expands AI capabilities for customer experience platform, adds AI-native applications, and provides new distribution channel to reach enterprises not yet cloud-migrated.
Market attention has faded.
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 5 Nov 2026Software / SaaS
Five9, Inc.FIVN
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 5 Nov 2026Industrials
Pacific Biosciences Of California, Inc.PACB
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
10-QFiled 5 Nov 2026Industrials
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
8-KFiled 5 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Celsius Holdings reported record Q3 2026 revenue of $847.2M (+17% YoY), driven by Alani Nu growth (+24%) and international expansion (+78%). CELSIUS brand declined 6% due to optimization. Gross margin compressed 450 bps to 46.8% from commodity inflation and DSD mix shift.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 5 Nov 2026Software / SaaS
8-K · Items 2.02, 8.01 — Results of operations
Q3 2026 revenues $1.426B (+2.3% YoY), GAAP EPS $2.53 (+32.5%), non-GAAP EPS $3.51 (+14.0%). Operating margins expanded. Board approved $1.8B repurchase authorization; $500M ASR planned. Full-year guidance raised; 50% free cash flow return commitment through 2029.
More of the market is starting to notice.
The price trend strengthened.
10-QFiled 5 Nov 2026Software / SaaS
Quarterly report (10-Q), period ending 30 Sep 2026
More of the market is starting to notice.
The price trend strengthened.
8-KFiled 5 Nov 2026All industries
Trupanion, Inc.TRUP
8-K · Item 2.02 — Results of operations
Q3 2026 earnings show record cash flow, seventh consecutive quarter of retention improvement, 11% revenue growth to $405.6M, and net income of $9.3M ($0.21 EPS). Company repurchased $25M stock and holds $396.8M cash.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 5 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Barings BDC reported Q3 2026 results with net investment income of $0.26 per share covering its dividend. NAV per share remained stable at $10.92. Portfolio grew to $2.5B with $196M funded investments. Board declared $0.26 quarterly dividend.
No notable change in AIR's read.
10-QFiled 5 Nov 2026All industries
Interactive Brokers Group, Inc.IBKR
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became dearer on AIR's value read.
The price trend weakened.
8-KFiled 5 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Q3 2026 earnings: NII $0.89/share, DNII $0.96/share, NAV $34.22/share (+0.9% QoQ). Declared 3.9% increase in Q4 regular monthly dividends and 21st consecutive supplemental dividend of $0.30/share. ROE 14.7% annualized.
Progress is running ahead of attention.
8-KFiled 5 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Q3 2026: GAAP net loss of $194M ($2.31/share); book value fell to $14.82/share; economic return of -13.98%. Significant mark-to-market losses on financial instruments ($391M) driven by interest rate and mortgage spread volatility.
The gap narrowed as the filings read less positively.
8-KFiled 5 Nov 2026Industrials
8-K · Item 2.02 — Results of operations
Q3 2026 net sales declined 10.1% YoY to $338.4M. GAAP net loss of $109.6M ($2.61/share) driven by $121.3M divestiture loss. Adjusted net income improved to $0.54/share, but operational headwinds persist: supply disruptions, higher input costs, and AAG/SSG weakness partially offset PVG gains.
More of the market is starting to notice.
The price trend strengthened.
8-KFiled 5 Nov 2026Software / SaaS
8-K · Item 2.02 — Results of operations
Q3 2026 revenue of $151.4M (+2.7% YoY) missed guidance low end; CEO cited non-MRR delays and weak organic search acquisition. FY2026 guidance reduced to $600M revenue and $170M Adjusted EBITDA. Leadership changes underway; management expects recovery by late 2027.
No notable change in AIR's read.
8-KFiled 5 Nov 2026Software / SaaS
8-K · Item 2.02 — Results of operations
Playtika reported Q3 2026 revenue of $673.8M (flat YoY, -7.8% QoQ) and record Adjusted EBITDA of $252.1M (+15.9% YoY). Board concluded strategic review, choosing to remain independent. Reaffirmed full-year guidance.
No notable change in AIR's read.
10-QFiled 5 Nov 2026Software / SaaS
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
10-QFiled 5 Nov 2026Banks
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became dearer on AIR's value read.
The price trend strengthened.
10-QFiled 5 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
8-KFiled 5 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Q3 2026 results show strong operational momentum: RevPAR surged 8%+ to $161 (all-time Q3 high), net income more than doubled, AFFO per share jumped 31% to $0.46, and margins expanded significantly (GOP +110 bps, Adjusted Hotel EBITDA +190 bps).
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 5 Nov 2026Software / SaaS
AvePoint, Inc.AVPT
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became dearer on AIR's value read.
Progress is running ahead of attention.
8-KFiled 5 Nov 2026Biotech
8-K · Item 2.02 — Results of operations
Q3 2026 NERLYNX sales grew YoY to $54.1M despite gross-to-net headwinds. Company raised full-year 2026 net income guidance to $20–$22M (from $17–$20M). R&D spending increased on alisertib trials; cash position strengthened to $108.5M.
AIR measured this for the first time; no change to report.
Market attention has faded.
The shares became cheaper on AIR's value read.
The price trend weakened.
10-QFiled 5 Nov 2026Banks
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became cheaper on AIR's value read.
The price trend strengthened.
10-QFiled 5 Nov 2026Biotech
Agios Pharmaceuticals, Inc.AGIO
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
10-QFiled 5 Nov 2026All industries
Dutch Bros Inc.BROS
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 5 Nov 2026Banks
Northwest Bancshares, Inc.NWBI
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
10-QFiled 5 Nov 2026Biotech
Xeris Biopharma Holdings, Inc.XERS
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 5 Nov 2026Software / SaaS
N-able, Inc.NABL
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 5 Nov 2026Software / SaaS
N-able, Inc.NABL
8-K · Item 2.02 — Results of operations
N-able reported Q3 2026 results with 4.9% YoY revenue growth and 5% ARR growth at constant currency, exceeding guidance. Updated full-year ARR outlook to $558M–$560M. Repurchased ~5% of shares; expanded partnerships and launched AI-powered products.
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 5 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Tecnoglass reported Q3 2026 record revenue of $310.6M (+19.2% YoY), driven by 31% multi-family/commercial growth. Net income $22.8M ($0.51/share); adjusted net income $27.3M ($0.61/share). Backlog hit record $1.43B (+13.2% YoY). Raised FY2026 guidance.
More of the market is starting to notice.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 5 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Q3 2026 Adjusted EBITDA hit record $95.3M; Long Ridge sale regulatory approval received; $255M USD Group energy logistics acquisition agreed. Despite GAAP net loss of $150M, operational metrics and strategic progress are strong.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 5 Nov 2026All industries
Apple Hospitality REIT, Inc.APLE
8-K · Item 2.02 — Results of operations
Q3 2026 earnings show strong growth: net income up 18.9% YoY, RevPAR up 7.3%, EBITDA margin expanded 210 bps. Company executing portfolio optimization (5 hotels contracted for sale, $72M) and refinanced debt favorably. October preliminary data shows 10% RevPAR growth.
Progress is running ahead of attention.
8-KFiled 5 Nov 2026Industrials
8-K · Item 2.02 — Results of operations
Warby Parker reported Q3 2026 revenue of $244.7M (+10.4% YoY), gross margin of 54.4% (+30 bps), and net income of $5.6M. Active customers grew 3.0% to 2.74M; ARPU increased 6.7% to $342. Company narrowed full-year revenue guidance to $966–976M and reaffirmed Adjusted EBITDA guidance of $117–119M. Intelligent Eyewear pre-orders begin November 12.
More of the market is starting to notice.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 5 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Q3 2026 adjusted net earnings of $0.74/share declined 39% YoY from $1.22/share. Net sales fell 50% to $1.4B. Adjusted ROE and ROA both declined. Despite record AUM and core retail sales, profitability metrics weakened significantly.
More of the market is starting to notice.
The price trend strengthened.
8-KFiled 5 Nov 2026Software / SaaS
Doximity, Inc.DOCS
8-K · Item 2.02 — Results of operations
Q2 FY2027 revenue grew 4% YoY to $174.5M, but net income fell 44% to $34.7M. Adjusted EBITDA declined 12% to $88.9M with margin compression from 59.8% to 50.9%. FY2027 guidance reduced at midpoint.
Market attention has faded.
The gap closed as the filings read less positively.
10-QFiled 5 Nov 2026Software / SaaS
Doximity, Inc.DOCS
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
The gap closed as the filings read less positively.
8-KFiled 5 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Market attention has faded.
The price trend weakened.
8-KFiled 5 Nov 2026Industrials
Solventum CorpSOLV
8-K · Item 2.02 — Results of operations
Solventum reported Q3 2026 results with organic sales decline of 2.8% due to expected ERP cutover timing effects. Company raised full-year adjusted EPS guidance to $7.20–$7.30 and expects organic sales growth toward high end of 2.5–3.0% range. Separation ~90% complete.
More of the market is starting to notice.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 5 Nov 2026Industrials
8-K · Item 2.02 — Results of operations
Karman reported record Q3 2026 revenue of $202M (+66% YoY), net income of $21M (+174% YoY), and adjusted EBITDA of $61M (+60% YoY). Backlog doubled to $1.7B. FY2026 guidance raised to $755–760M revenue and $225–227M adjusted EBITDA.
No notable change in AIR's read.
8-KFiled 5 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Regency Centers reported Q3 2026 results with FFO of $1.23/share and raised full-year FFO guidance to $4.86–$4.88. Same-property NOI grew 5.1% YoY. Board increased common dividend 6% to $0.80/share. Portfolio 97% leased.
No notable change in AIR's read.
10-QFiled 5 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
8-KFiled 5 Nov 2026Biotech
8-K · Item 2.02 — Results of operations
Avalo reported Q3 2026 results with positive Phase 2 LOTUS data for abdakibart in hidradenitis suppurativa, planning Phase 3 initiation H1 2027. Strong cash position of $462.8M funds operations into 2029. AVTX-010 IND submission planned H1 2027.
No notable change in AIR's read.
10-QFiled 5 Nov 2026Biotech
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
10-QFiled 5 Nov 2026Banks
S&T Bancorp IncSTBA
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became cheaper on AIR's value read.
10-QFiled 5 Nov 2026All industries
Six Flags Entertainment Corporation/NEWFUN
Quarterly report (10-Q), period ending 27 Sep 2026
No notable change in AIR's read.
8-KFiled 5 Nov 2026All industries
Carlyle Secured Lending, Inc.CGBD
8-K · Item 2.02 — Results of operations
CGBD reported Q3 2026 net investment income of $0.36 per share, fully covering its $0.35 dividend. NAV increased 0.3% to $15.65. Portfolio stable at $2.3B across 180 companies with 10.8% weighted average yield. Q4 dividend declared at $0.35/share.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 5 Nov 2026All industries
Concentra Group Holdings Parent, Inc.CON
8-K · Items 2.02, 8.01 — Results of operations
Q3 2026 revenue grew 8.6% YoY to $622.1M; net income surged 36.5% YoY. Company raised FY2026 guidance across revenue, EBITDA, and FCF. Board authorized $250M share repurchase and declared $0.0625 dividend. Credit ratings upgraded.
No notable change in AIR's read.
8-KFiled 5 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Q3 2026 net income declined 12% sequentially to $93.5M ($1.23 EPS) from Q2's $105.8M ($1.38 EPS). Loss ratio spiked to 18.7% from 8.3% Q/Q. Insurance claims rose 121% Q/Q to $29.1M. ROE fell to 13.8% from 15.9%.
Market attention has faded.
The gap closed as the filings read less positively.
The price trend weakened.
10-QFiled 5 Nov 2026All industries
Progyny, Inc.PGNY
Quarterly report (10-Q), period ending 30 Sep 2026
More of the market is starting to notice.
The shares became dearer on AIR's value read.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 5 Nov 2026Industrials
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
8-KFiled 5 Nov 2026Biotech
Prothena Corp Public Ltd CoPRTA
8-K · Item 2.02 — Results of operations
Q3 2026 results show improved net loss ($16.5M vs $36.5M YoY), $272.2M cash position, and positive clinical data for coramitug (hsCRP biomarker reduction). Phase 3 trials for prasinezumab and coramitug progressing toward 2029 completion.
No notable change in AIR's read.
10-QFiled 5 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 5 Nov 2026All industries
Installed Building Products, Inc.IBP
Quarterly report (10-Q), period ending 30 Sep 2026
More of the market is starting to notice.
The price trend strengthened.
8-KFiled 5 Nov 2026Biotech
8-K · Item 2.02 — Results of operations
Dyne reported Q3 2026 results with $1.134B cash position sufficient through Q2 2028. Lead candidate z-rostudirsen under FDA priority review (PDUFA Jan 21, 2027); z-basivarsen Phase 1/2 data supports efficacy; four preclinical DMD programs advancing. Higher R&D and G&A expenses reflect commercialization preparations.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 5 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
8-KFiled 5 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Q3 2026 net sales grew 3.1% to $1.82B with improved gross margin (30.4% vs 29.9%). Adjusted EBITDA increased 1.6% to $411M. Company updated 2026 guidance: Net Sales at midpoint of prior range; Adjusted EBITDA at lower end. Authorized $300M share repurchase program.
Progress is running ahead of attention.
The price trend strengthened.
Sun 22 Nov
CAPR · Capricor Therapeutics, Inc. · Regulatory date
As stated in the filing: “Deramiocel Biologics License Application (BLA) for Duchenne muscular dystrophy (DMD) under FDA review; PDUFA target action date of November 22, 2026 ●”
Announced by the company in 8-K on 10 Nov 2026
DYN · Dyne Therapeutics, Inc. · Regulatory date
As stated in the filing: “Capricor Therapeutics’ BLA for its cell therapy deramiocel is currently under FDA review with a PDUFA date of November 22, 2026.”
Announced by the company in 10-Q on 5 Nov 2026
SVRA · Savara Inc · Regulatory date
As stated in the filing: “The FDA determined that the Company’s responses to recent information requests by the Agency during its review constituted a major amendment to the BLA, resulting in a three-month extension of the Prescription Drug User Fee Act ("PDUFA") target action date to November 22, 2026.”
Announced by the company in 10-Q on 9 Nov 2026
Fri 27 Nov
BBIO · BridgeBio Pharma, Inc. · Regulatory date
As stated in the filing: “The first participant was dosed in ASCEND-ATTR, the Phase 3b/4 study to prospectively test disease reversal with Attruby - BBP-418 for LGMD2I/R9 has a November 27, 2026 PDUFA date, with Priority Review.”
Announced by the company in 8-K on 29 Oct 2026
Mon 30 Nov
COGT · Cogent Biosciences, Inc. · Regulatory date
As stated in the filing: “Potential FDA approval of bezuclastinib in GIST – PDUFA date of November 30, 2026 •”
Announced by the company in 8-K on 5 Nov 2026
JBIO · Jade Biosciences, Inc. · Regulatory date
As stated in the filing: “The FDA has also accepted a Biologics License Application for accelerated approval of povetacicept in IgAN, with a Prescription Drug User Fee Act target action date of November 30, 2026.”
Announced by the company in 10-Q on 13 Nov 2026
Wed 2 Dec
ARE · Alexandria Real Estate Equities, Inc. · Investor day
As stated in the filing: “We expect to introduce 2027 guidance and related assumptions at our Investor Day on December 2, 2026, consistent with our historical practice.”
Announced by the company in 8-K on 27 Apr 2026
Thu 3 Dec
EXEL · Exelixis, Inc. · Regulatory date
As stated in the filing: “In February 2026, we announced that the FDA had accepted our NDA and assigned a standard review, with a Prescription Drug User Fee Act (PDUFA) target action date of December 3, 2026.”
Announced by the company in 10-Q on 29 Oct 2026
Tue 8 Dec
GPC · Genuine Parts Co · Investor day
As stated in the filing: “In addition, the Company announced that both Global Automotive and Global Industrial will host separate investor days on December 8, 2026 and December 9, 2026, respectively.”
Announced by the company in 8-K on 9 Sep 2026
LGND · Ligand Pharmaceuticals Inc · Investor day
As stated in the filing: “Ligand will provide an updated 5-year outlook during the Company’s Investor Day on December 8, 2026.”
Announced by the company in 8-K on 14 Jul 2026
Wed 9 Dec
GPC · Genuine Parts Co · Investor day
As stated in the filing: “Investor Days GPC and Motion will host separate investor days in New York City, with GPC’s Investor Day scheduled for December 8, 2026, and Motion’s Investor Day scheduled for December 9, 2026.”
Announced by the company in 8-K on 9 Sep 2026
Sat 12 Dec
ANAB · Anaptysbio, Inc · Regulatory date
As stated in the filing: “FDA target action date (PDUFA) of December 12, 2026, for Quimilza in generalized pustular psoriasis (GPP) GSK and Tesaro Litigation Update •”
Announced by the company in 8-K on 12 Nov 2026
Thu 17 Dec
CORT · Corcept Therapeutics Inc · Regulatory date
As stated in the filing: “Relacorilant for patients with Cushing’s syndrome – Resubmitted New Drug Application Prescription Drug User Fee Act (PDUFA) date of December 17, 2026 “The ADA and EASD consensus statement is an important advance for the many patients whose difficult-to-control hyperglycemia is a manifestation of undiagnosed Cushing’s syndrome,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer.”
Announced by the company in 8-K on 3 Nov 2026
Mon 23 Nov
MATW · Matthews International Corp · All industries
Annual results due — last year filed 21 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue down 30%, net income turned to a loss
AIR's current read: News flow Balanced, Gap Low · 0
Tue 24 Nov
BLBD · Blue Bird Corp · Industrials
Annual results due — last year filed 24 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 30%, net income up 408%
AIR's current read: News flow Balanced, Gap Very high · 82
PFLT · PennantPark Floating Rate Capital Ltd. · All industries
Annual results due — last year filed 24 Nov 2025
AIR's current read: News flow Balanced, Gap Very high · 71
Wed 25 Nov
AMTM · Amentum Holdings, Inc. · All industries
Annual results due — last year filed 25 Nov 2025
Last quarter (Q3 2025, against a year earlier): revenue up 66%, net income turned positive
AIR's current read: News flow Balanced, Gap Low · 4
ARMK · Aramark · All industries
Annual results due — last year filed 25 Nov 2025
Last quarter (Q3 2025, against a year earlier): revenue up 6%, net income up 23%
AIR's current read: News flow Balanced, Gap Medium · 10
CASH · Pathward Financial, Inc. · Banks
Annual results due — last year filed 25 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue down 3%, net income down 31%
AIR's current read: News flow Balanced, Gap Low · 0
CLSK · Cleanspark, Inc. · Banks
Annual results due — last year filed 25 Nov 2025
Last quarter (Q3 2024, against a year earlier): revenue up 129%, net loss widened
AIR's current read: News flow Balanced, Gap Very high · 54
GAP · Gap Inc · All industries
Quarterly results due — last year filed 25 Nov 2025
Last quarter (Q3 2024, against a year earlier): revenue down 7%, net income down 23%
AIR's current read: News flow Balanced, Gap Low · 3
ROAD · Construction Partners, Inc. · All industries
Annual results due — last year filed 25 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 28%, net income up 35%
AIR's current read: News flow Balanced, Gap Low · 7
SJM · J M SMUCKER Co · All industries
Quarterly results due — last year filed 25 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 7%, net loss widened
AIR's current read: News flow Balanced, Gap Low · 7
SMG · Scotts Miracle-Gro Co · All industries
Annual results due — last year filed 25 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 1%, net income down 25%
AIR's current read: News flow Balanced, Gap Medium · 12
SMTC · Semtech Corp · Semiconductors
Quarterly results due — last year filed 25 Nov 2025
Last quarter (Q1 2027, against a year earlier): revenue up 16%, net income up 37%
AIR's current read: News flow Balanced, Gap Low · 0
TFSL · TFS Financial CORP · Banks
Annual results due — last year filed 25 Nov 2025
Last quarter (Q1 2019, against a year earlier): net income up 4%
AIR's current read: News flow Balanced, Gap Medium · 23
Fri 27 Nov
ATKR · Atkore Inc. · Industrials
Annual results due — last year filed 26 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 8%, net income down 98%
AIR's current read: News flow Balanced, Gap Low · 0
BJ · BJ's Wholesale Club Holdings, Inc. · All industries
Quarterly results due — last year filed 26 Nov 2025
Last quarter (Q2 2027, against a year earlier): revenue up 16%, net income up 15%
AIR's current read: News flow Balanced, Gap Medium · 18
CENT · Central Garden & Pet Co · All industries
Annual results due — last year filed 26 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue down 8%, net income down 5%
AIR's current read: News flow Balanced, Gap Low · 1
CFFN · Capitol Federal Financial, Inc. · Banks
Annual results due — last year filed 26 Nov 2025
Last quarter (Q3 2020, against a year earlier): net income down 15%
AIR's current read: News flow Balanced, Gap Medium · 10
JJSF · J&J Snack Foods Corp · All industries
Annual results due — last year filed 26 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue down 6%, net income down 20%
AIR's current read: News flow Balanced, Gap Low · 0
PD · PagerDuty, Inc. · Software / SaaS
Quarterly results due — last year filed 26 Nov 2025
Last quarter (Q1 2027, against a year earlier): revenue up 1%, net income turned positive
AIR's current read: News flow Balanced, Gap Low · 0
SPH · Suburban Propane Partners Lp · All industries
Annual results due — last year filed 26 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue unchanged, net loss widened
AIR's current read: News flow Balanced, Gap Medium · 21
UTI · Universal Technical Institute Inc · All industries
Annual results due — last year filed 26 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 7%, net income down 79%
AIR's current read: News flow Balanced, Gap Very high · 57
Mon 30 Nov
SNEX · StoneX Group Inc. · All industries
Annual results due — last year filed 28 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 15%, net income up 102%
AIR's current read: News flow Balanced, Gap Very high · 52
Tue 1 Dec
ESE · Esco Technologies Inc · Industrials
Annual results due — last year filed 1 Dec 2025
Last quarter (Q3 2026, against a year earlier): revenue up 14%, net income up 26%
AIR's current read: News flow Balanced, Gap Very high · 97
Wed 2 Dec
ASAN · Asana, Inc. · Software / SaaS
Quarterly results due — last year filed 2 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 10%, net loss narrowed
AIR's current read: News flow Balanced, Gap Low · 0
UNFI · United Natural Foods Inc · All industries
Quarterly results due — last year filed 2 Dec 2025
AIR's current read: News flow Balanced, Gap Low · 0
VSTS · Vestis Corp · All industries
Annual results due — last year filed 2 Dec 2025
Last quarter (Q3 2025, against a year earlier): revenue down 4%, net income turned to a loss
AIR's current read: News flow Balanced, Gap Low · 1
Thu 3 Dec
BOX · Box Inc · Software / SaaS
Quarterly results due — last year filed 3 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 9%, net income up 43%
AIR's current read: News flow Balanced, Gap Low · 1
CRWD · CrowdStrike Holdings, Inc. · Software / SaaS
Quarterly results due — last year filed 3 Dec 2025
Last quarter (Q1 2027, against a year earlier): revenue up 26%, net income turned positive
AIR's current read: News flow Balanced, Gap Low · 5
HQY · Healthequity, Inc. · All industries
Quarterly results due — last year filed 3 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 8%, net income up 10%
AIR's current read: News flow Balanced, Gap Low · 0
KSS · KOHLS Corp · All industries
Quarterly results due — last year filed 3 Dec 2025
Last quarter (Q3 2024, against a year earlier): revenue down 5%, net income down 39%
AIR's current read: News flow Balanced, Gap Medium · 11
MEI · Methode Electronics Inc · Industrials
Quarterly results due — last year filed 3 Dec 2025
AIR's current read: News flow Balanced, Gap Low · 0
NCNO · nCino, Inc. · Software / SaaS
Quarterly results due — last year filed 3 Dec 2025
Last quarter (Q1 2027, against a year earlier): revenue up 11%, net income up 145%
AIR's current read: News flow Balanced, Gap Low · 5
THO · Thor Industries Inc · Industrials
Quarterly results due — last year filed 3 Dec 2025
Last quarter (Q4 2026, against a year earlier): revenue down 8%, net income down 68%
AIR's current read: News flow Balanced, Gap Low · 4
Fri 4 Dec
AGX · Argan Inc · All industries
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 62%, net income up 51%
AIR's current read: News flow Balanced, Gap Low · 9
AMBA · Ambarella Inc · Semiconductors
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 13%, net loss narrowed
AIR's current read: News flow Balanced, Gap Low · 7
BF-B · Brown Forman Corp · All industries
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q1 2027, against a year earlier): revenue down 1%, net income up 4%
AIR's current read: News flow Balanced, Gap Low · 0
CXM · Sprinklr, Inc. · Software / SaaS
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 1%, net income down 44%
AIR's current read: News flow Balanced, Gap Low · 9
DCI · DONALDSON Co INC · All industries
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q4 2026, against a year earlier): revenue up 8%, net income up 13%
AIR's current read: News flow Balanced, Gap Low · 9
FIVE · Five Below, Inc · All industries
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q3 2024, against a year earlier): revenue up 14%, net income down 10%
AIR's current read: News flow Balanced, Gap High · 27
GWRE · Guidewire Software, Inc. · Software / SaaS
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q3 2026, against a year earlier): revenue up 27%, net income down 64%
AIR's current read: News flow Balanced, Gap High · 44
NTNX · Nutanix, Inc. · Software / SaaS
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q3 2026, against a year earlier): revenue up 10%, net income up 14%
AIR's current read: News flow Balanced, Gap Medium · 22
REX · REX AMERICAN RESOURCES Corp · All industries
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 6%, net income up 336%
AIR's current read: News flow Balanced, Gap Low · 0
SAIC · Science Applications International Corp · Software / SaaS
Quarterly results due — last year filed 4 Dec 2025
AIR's current read: News flow Balanced, Gap High · 39
SWBI · Smith & Wesson Brands, Inc. · Industrials
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q1 2027, against a year earlier): revenue up 32%, net income turned positive
AIR's current read: News flow Balanced, Gap Very high · 87
TITN · Titan Machinery Inc. · All industries
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue down 9%, net loss widened
AIR's current read: News flow Balanced, Gap Low · 0
Expected dates come from each company's filing history. They are not forecasts, and companies move them.
Sign in to follow companies
Follow a company and its filings show up here.
Sign inResearch, not tips. Filings come from SEC EDGAR; AIR's read is recomputed every trading day. A price move is shown as a fact beside a filing, never as the reason it is listed.